While classification of BC is constantly evolving with scientific advances on the field, its classical subdivision into four distinct clinical subgroups is based on the expression of hormone receptors (HR) and human epidermal growth factor receptor 2 (HER2) in routine clinical practice. Here, ERBB2 is linked to breast cancer.